Abstract: Provided is a medical support arm system including a support arm that is a multilink structure having a plurality of links connected by a joint unit including an actuator, and supports a medical unit. The medical support arm system further includes a control device including an external force estimation unit to estimate an external force acting on the joint unit on the basis of a drive characteristic of the actuator, and a joint control unit to control drive of the joint unit on the basis of an external torque estimated by the external force estimation unit.

Abstract: The present invention provides a new imidazole derivative represented by the following formula or a pharmaceutically acceptable salt thereof which exhibits potent antimicrobial activity based on a LpxC-inhibiting action against gram-negative bacteria such as Pseudomonas aeruginosa, Escherichia coli, and Klebsiella pneumoniae, and their drug-resistant strains. General formula [1] or [2].

Abstract: In order to suppress oscillation and malfunction of a switching element in a power converter, the power converter includes a switching element; and an oscillation suppression circuit having a stub which is electrically connected to a terminal of the switching element. A signal of the oscillation frequency is suppressed based on a length of the stub relative to a wavelength of the oscillation frequency. When an incident wave reflects from the open end of the stub, the reflected wave is out of phase with the incident wave, and the incident wave and the reflected wave cancel each other.

Abstract: Provided is an amino acid derivative prodrug represented by general formula (I-A) that is a prodrug form of an amino acid derivative which is a group 2 metabotropic glutamate receptor antagonist, or a pharmaceutically acceptable salt thereof. More specifically, provided is an amino acid derivative prodrug represented by general formula (I-A) that is a preventive or therapeutic drug for mood disorders (including depression and bipolar disorder), anxiety disorder, cognitive disorders, developmental disorders, Alzheimer's disease, Parkinson's disease, movement disorders associated with muscular rigidity, sleep disorders, Huntington's chorea, eating disorders, drug dependence, epilepsy, brain infarction, cerebral ischemia, cerebral insufficiency, cerebral edema, spinal cord disorders, head trauma, inflammation and immune-related diseases, and so on.

Abstract: Provided is an amino acid derivative prodrug represented by general formula (I-A) that is a prodrug form of an amino acid derivative which is a group 2 metabotropic glutamate receptor antagonist, or a pharmaceutically acceptable salt thereof. More specifically, provided is an amino acid derivative prodrug represented by general formula (I-A) that is a preventive or therapeutic drug for mood disorders (including depression and bipolar disorder), anxiety disorder, cognitive disorders, developmental disorders, Alzheimer's disease, Parkinson's disease, movement disorders associated with muscular rigidity, sleep disorders, Huntington's chorea, eating disorders, drug dependence, epilepsy, brain infarction, cerebral ischemia, cerebral insufficiency, cerebral edema, spinal cord disorders, head trauma, inflammation and immune-related diseases, and so on.

Abstract: Provided is an amino acid derivative prodrug represented by general formula (I-A) that is a prodrug form of an amino acid derivative which is a group 2 metabotropic glutamate receptor antagonist, or a pharmaceutically acceptable salt thereof. More specifically, provided is an amino acid derivative prodrug represented by general formula (I-A) that is a preventive or therapeutic drug for mood disorders (including depression and bipolar disorder), anxiety disorder, cognitive disorders, developmental disorders, Alzheimer's disease, Parkinson's disease, movement disorders associated with muscular rigidity, sleep disorders, Huntington's chorea, eating disorders, drug dependence, epilepsy, brain infarction, cerebral ischemia, cerebral insufficiency, cerebral edema, spinal cord disorders, head trauma, inflammation and immune-related diseases, and so on.

Abstract: In order to suppress oscillation and malfunction of a switching element in a power converter, the power converter includes a switching element; and an oscillation suppression circuit having a stub which is electrically connected to a terminal of the switching element.

Abstract: A novel process for producing optically active 2-(2-fluorobiphenyl-4-yl)propanoic acid is disclosed. This production process is characterized in that a compound of formula [1] is reacted with magnesium and so forth to prepare an organometallic reagent, which is reacted with a compound of formula [2] in the presence of a catalytic amount of a nickel compound and a catalytic amount of an optically active compound of formula [3] to obtain a compound represented by formula [4] which is subsequently converted to a compound represented by formula [5] or a pharmaceutically acceptable salt thereof.

Abstract: Provided is an amino acid derivative prodrug represented by general formula (I-A) that is a prodrug form of an amino acid derivative which is a group 2 metabotropic glutamate receptor antagonist, or a pharmaceutically acceptable salt thereof. More specifically, provided is an amino acid derivative prodrug represented by general formula (I-A) that is a preventive or therapeutic drug for mood disorders (including depression and bipolar disorder), anxiety disorder, cognitive disorders, developmental disorders, Alzheimer's disease, Parkinson's disease, movement disorders associated with muscular rigidity, sleep disorders, Huntington's chorea, eating disorders, drug dependence, epilepsy, brain infarction, cerebral ischemia, cerebral insufficiency, cerebral edema, spinal cord disorders, head trauma, inflammation and immune-related diseases, and so on.

Abstract: A novel process for producing optically active 2-(2-fluorobiphenyl-4-yl)propanoic acid is disclosed. This production process is characterized in that a compound of formula [1] is reacted with magnesium and so forth to prepare an organometallic reagent, which is reacted with a compound of formula [2] in the presence of a catalytic amount of a nickel compound and a catalytic amount of an optically active compound of formula [3] to obtain a compound represented by formula [4] which is subsequently converted to a compound represented by formula [5] or a pharmaceutically acceptable salt thereof.

Abstract: An isolated DC/DC converter (3) includes a full-bridge type switching circuit. A primary winding of a transformer (6) and a resonance reactor (5) are connected in series to each other. Another end of each of the primary winding and the resonance reactor (5) is connected to one of middle points between switching elements. First and second surge suppression diodes (D5 and D6) are provided to a node between the resonance reactor (5) and the primary winding of the transformer (6) and between a positive side and a negative side of a capacitor (4). This configuration suppresses a surge voltage applied to the transformer by releasing surge energy of the resonance reactor (5) caused by a recovery of rectifying diodes (D1 to D4) on a secondary side of the transformer (6) via the surge suppression diodes (D5 and D6).

Abstract: According to one embodiment, a vehicle lighting device includes a base body that has a plate shape and includes a first portion, and a second portion having a width dimension smaller than a width dimension of the first portion; a wiring pattern that is provided on surfaces of the first portion and the second portion; and a light emitting element that is electrically connected to the wiring pattern provided in the first portion.

Abstract: An isolated DC/DC converter (3) includes a full-bridge type switching circuit. A primary winding of a transformer (6) and a resonance reactor (5) are connected in series to each other. Another end of each of the primary winding and the resonance reactor (5) is connected to one of middle points between switching elements. First and second surge suppression diodes (D5 and D6) are provided to a node between the resonance reactor (5) and the primary winding of the transformer (6) and between a positive side and a negative side of a capacitor (4). This configuration suppresses a surge voltage applied to the transformer by releasing surge energy of the resonance reactor (5) caused by a recovery of rectifying diodes (D1 to D4) on a secondary side of the transformer (6) via the surge suppression diodes (D5 and D6).

Abstract: A lighting device is provided that includes: a light emitting section that has a light emitting element and a switch for controlling a lighting state of the light emitting element; a housing that stores the light emitting section and has one end section which is open; a translucent cover that covers the opening of the housing; and a frame that is provided between the housing and the cover. The frame includes an edge section that presents a frame shape and a holding section having one end provided in the edge section and the other end protruding from the edge section. The holding section holds an operation section operating the switch and is exposed from the cover.

Abstract: The present invention provides novel compounds of formula [IA] or pharmaceutically acceptable salts thereof: which are useful in the prevention or treatment of diseases such as schizophrenia, Alzheimer's disease, cognitive impairment, dementia, anxiety disorders (e.g., generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, acute stress disorder), depression, drug dependence, spasm, tremor, pain, Parkinson's disease, attention deficit hyperactivity disorder, bipolar disorder, eating disorder, or sleep disorders, which is based on the glycine uptake-inhibiting action.

Abstract: According to one embodiment, there is provided a vehicle interior lighting device including a plurality of light-emitting elements, a switch for switching an ON mode for lighting at least a part of the plurality of light-emitting elements and a DOOR mode for lighting at least a part of the plurality of light-emitting elements when a door of a vehicle is in an open state and extinguishing the plurality of light-emitting elements when doors of the vehicle are in a closed state, and a control section configured to control light-emitting states of the plurality of light-emitting elements to set an amount of light in the DOOR mode to be more than an amount of light in the ON mode.

Abstract: According to an embodiment, a lighting device includes: a light emitting section that has a light emitting element and a switch for controlling a lighting state of the light emitting element; a housing that stores the light emitting section and of which one end section is open; a cover that covers the opening of the housing and has translucency; and a frame that is provided between the housing and the cover. The frame includes an edge section that presents a frame shape and a holding section of which one end is provided in the edge section and the other end protrudes from the edge section, and which holds an operation section operating the switch and is exposed from the cover.

Abstract: Provided is a novel compound represented by formula [I] or a pharmaceutically acceptable salt thereof having antagonistic activity against group II metabolism-type glutamic acid (m-Glu) receptors. The compound or pharmaceutically acceptable salt thereof is useful as a prophylactic or therapeutic agent for diseases such as new mood disorders (depressive and bipolar disorders), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, and acute stress disorder), schizophrenia, Alzheimer's disease, cognitive dysfunction, dementia, drug dependence, convulsions, tremors, pain, sleep disorders, and the like.

Abstract: A compound represented by formula [I] and a pharmaceutically accepted salt of said compound are a novel compound and a pharmaceutically accepted salt thereof which exert antagonistic activity against group II metabotropic glutamate (mGlu) receptors, and are effective as a novel preventive or therapeutic agent for disorders such as mood disorders (depressive disorder, bipolar disorder, etc.), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, posttraumatic stress disorder, a specific phobic disorder, acute stress disorder, etc.), schizophrenia, Alzheimer's disease, cognitive impairment, dementia, drug dependence, convulsions, shivering, pain, sleep disorders, and the like.

Abstract: Provided is a novel compound represented by formula [I] or a pharmaceutically acceptable salt thereof having antagonistic activity against group II metabolism-type glutamic acid (m-Glu) receptors. The compound or pharmaceutically acceptable salt thereof is useful as a prophylactic or therapeutic agent for diseases such as new mood disorders (depressive and bipolar disorders), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, and acute stress disorder), schizophrenia, Alzheimer's disease, cognitive dysfunction, dementia, drug dependence, convulsions, tremors, pain, sleep disorders, and the like.